Annual report [Section 13 and 15(d), not S-K Item 405]

Segment Information

v3.25.1
Segment Information
12 Months Ended
Dec. 31, 2024
Segment Information  
Segment Information

9. Segment Information

 

Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision maker (“CODM”), in deciding how to allocate resources and in assessing performance. The Company and the Company’s chief operating decision maker view the Company’s operations and manage its business in one operating segment, which is the business of identifying, developing, and commercializing pharmaceutical products for the treatment of medical and aesthetic skin conditions and diseases. 

 

The CODM, who is the Chief Executive Officer (“CEO”), President, and Chairman of the Board, manages and allocates resources to the operations of the Company on an entity-wide basis. The Company’s measure of segment profit or loss is net loss. Managing and allocating resources on an entity-wide basis enables the CEO to assess the overall level of resources available and how to best deploy these resources across functions and research and development projects that are in line with the Company’s long-term company-wide strategic goals. Consistent with this decision-making process, the CEO uses financial information for purposes of evaluating performance, forecasting future period financial results, allocating resources, and setting incentive targets. Operating expenses are used to monitor budget versus actual results. The CODM does not review assets in evaluating the results of the Company, and therefore, such information is not presented.

 

The following table summarizes the segment's financial information including the Company’s significant segment expenses:

 

 

 

Years Ended

December 31,

 

 

 

2024

 

 

2023

 

Research and development

 

$

 

 

 

 

Clinical

 

 

5,796,196

 

 

 

869,379

 

Nonclinical

 

 

515,934

 

 

 

1,387,359

 

Personnel related

 

 

1,891,561

 

 

 

1,813,028

 

Total research and development

 

$ 8,203,691

 

 

$ 4,069,766

 

General and administrative

 

 

4,309,551

 

 

 

3,972,140

 

Interest income

 

 

225,781

 

 

 

247,216

 

Net loss

 

$ (12,287,461 )

 

 

(7,794,690 )